Navigation Links
Cepheid to Webcast Upcoming Financial Presentations
Date:8/22/2008

SUNNYVALE, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast.

Thomas Weisel Partners Healthcare Conference, Boston, MA

Wednesday, September 3, 2008 at 2.05 p.m. Eastern Time

R.W. Baird Small Cap Healthcare Conference, New York, NY

Wednesday, September 10, 2008 at 9.00 a.m. Eastern Time

UBS Global Life Sciences Conference, New York, NY

Tuesday, September 23, 2008 at 9.00 a.m. Eastern Time

Accessing Webcasts

To access the live webcasts for these events, please visit Cepheid's website at http://www.cepheid.com/investors at least 15 minutes before the schedule start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the presentation and will remain available for at least 90 days.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.

CONTACTS:

For Media Inquiries: For Investor Inquiries:

Jared Tipton Jacquie Ross

Cepheid Corporate Communications Cepheid Investor Relations

Tel: (408) 400-8377 Tel: (408) 400-8329

jared.tipton@cepheid.com jacquie.ross@cepheid.com


'/>"/>
SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
2. Cepheid Reports Second Quarter Revenue of $42.1 Million
3. Cepheid to Webcast Analyst Event
4. Cepheid Schedules Fiscal 2008 Second Quarter Financial Results Announcement and Webcast
5. Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program
6. Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico
7. Cepheid Signs Group Purchasing Contract with Novation, the Nations Largest Healthcare Contracting Organization
8. Cepheid to Present at the Robert W. Baird Growth Stock Conference and the Bank of America Healthcare Conference
9. Cepheid Schedules Teleconference and Webcast for First Quarter 2008 Results
10. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
11. Cepheid Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2020)... , ... August 03, 2020 , ... Introducing Ardent Animal ... transformative growth, , Known as MediVet Biologics since its formation ... The new Ardent Animal Health will build on its base of innovative ...
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON Manufacturing, the leader in ... “BUILDING FOR LIFE.” The adoption of this taglines comes at a time of ... capacity to provide patients with urgently needed vaccines and other lifesaving pharmaceutical treatments. ...
(Date:7/31/2020)... ... July 29, 2020 , ... Anomet Products has introduced ... materials for use with CRM, neurostimulation, vascular, and related devices. , Anomet ... design requirements, performance, and cost criteria; especially where solid wire is limited. Typical ...
(Date:7/31/2020)... ... , ... eSource has long been touted as the solution to high data ... the reasons it did not take off as quickly as people initially expected, and ... moving towards capturing data electronically for clinical trials and then repurposing it for downstream ...
Breaking Biology Technology:
(Date:8/21/2020)... (PRWEB) , ... August 18, 2020 , ... ... to cell therapy, today announced that the U.S. Food and Drug Administration (FDA) ... Sentien’s lead asset, SBI-101, for the treatment of severe COVID-19. Approval of this ...
(Date:8/12/2020)... ... August 11, 2020 , ... Both Roche, ... have entered into license agreements with Housey Pharma’s HMI subsidiary to gain access ... J&J have annual Research and Development spending in excess of US $10 billion. ...
(Date:8/5/2020)... ... 05, 2020 , ... Regenative Labs has received approval from the Centers for ... them the first Wharton’s jelly allografts to be assigned a Q code and be ... the first Wharton’s jelly allograft product to be recognized as a 361 HCT/P by ...
Breaking Biology News(10 mins):